{"id":12679,"date":"2017-08-25T13:16:24","date_gmt":"2017-08-25T12:16:24","guid":{"rendered":"http:\/\/k2info.w.uib.no\/?p=12679"},"modified":"2017-08-25T13:32:02","modified_gmt":"2017-08-25T12:32:02","slug":"cost-nye-nettverk-innen-medisinsk-og-helsefaglig-forskning","status":"publish","type":"post","link":"https:\/\/k2info.w.uib.no\/nb_no\/2017\/08\/25\/cost-nye-nettverk-innen-medisinsk-og-helsefaglig-forskning\/","title":{"rendered":"[:no]COST: nye nettverk innen medisinsk og helsefaglig forskning[:en]COST: new networks in medical and health research[:]"},"content":{"rendered":"<p>[:no]COST er en europeisk nettverksorganisasjon der de fleste landene i Europa (herunder Norge og alle EU-landene) er medlemmer. En viktig oppgave for COST er \u00e5 fremme europeisk forskningssamarbeid ved \u00e5 igangsette vitenskapelige nettverk (&laquo;COST-aksjoner&raquo;).<\/p>\n<p>Generell informasjon om COST finnes <strong><a href=\"http:\/\/www.forskningsradet.no\/COST\">her<\/a><\/strong> og <strong><a href=\"http:\/\/www.cost.eu\/\">her<\/a><\/strong>.<\/p>\n<p>I juni 2017 ble det vedtatt \u00e5 igangsette 35 nye COST-aksjoner. En liste over de som er relevante for medisinsk og helsefaglig forskning, finnes nedenfor.<\/p>\n<p>Ved interesse for \u00e5 delta bes man om \u00e5 ta kontakt med <strong><a href=\"mailto:mailto:hh@forskningsradet.no\">Hans Hellebostad<\/a><\/strong> i Forskningsr\u00e5det innen\u00a0<strong>15.\u00a0september\u00a02017<\/strong>. (Dette er ikke n\u00f8dvendigvis siste mulighet for \u00e5 kunne bli med i aksjonene, men er satt som en f\u00f8rste frist av hensyn til Forskningsr\u00e5dets oppf\u00f8lging overfor COST.) Man kan da ogs\u00e5 f\u00e5 mer detaljert informasjon om deltakelse i COST. S\u00f8knadsskjema som brukes for \u00e5 kunne bli med som deltaker, finnes <a href=\"http:\/\/k2info.w.uib.no\/files\/2017\/08\/K2nytt_2017_Uke-34_COST_S\u00f8knad-om-deltagelse-i-COST-aksjon.doc\"><strong>her<\/strong><\/a>.<\/p>\n<p><!--more--><\/p>\n<p>I juni 2017 ble det vedtatt \u00e5 igangsette 35 nye COST-aksjoner, hvorav f\u00f8lgende er innenfor\/relevante for medisinsk og helsefaglig forskning:<\/p>\n<table>\n<tbody>\n<tr>\n<td width=\"446\">\u00b7\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0CA16203 \u2013 Stem cells of marine\/aquatic invertebrates: from basic research to innovative applications (<a href=\"http:\/\/www.cost.eu\/COST_Actions\/ca\/CA16203\">CA16203 &#8211; MARISTEM<\/a>)<\/td>\n<\/tr>\n<tr>\n<td width=\"446\">\u00b7\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0CA16205 \u2013 European Network on Understanding Gastrointestinal Absorption-related Processes (<a href=\"http:\/\/www.cost.eu\/COST_Actions\/ca\/CA16205\">CA16205 &#8211; UNGAP<\/a>)<\/td>\n<\/tr>\n<tr>\n<td width=\"446\">\u00b7\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0CA16207 \u2013 European Network for Problematic Usage of the Internet (<a href=\"http:\/\/www.cost.eu\/COST_Actions\/ca\/CA16207\">CA16207 &#8211; EU-PUI<\/a>)<\/td>\n<\/tr>\n<tr>\n<td width=\"446\">\u00b7\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0CA16210 \u2013 Maximising Impact of research in NeuroDevelopmental DisorderS<\/p>\n<p>(<a href=\"http:\/\/www.cost.eu\/COST_Actions\/ca\/CA16210\">CA16210 &#8211; MINDDS<\/a>)<\/td>\n<\/tr>\n<tr>\n<td width=\"446\">\u00b7\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0CA16216 \u2013 Coordination and Harmonization of European Occupational Cohorts<\/p>\n<p>(<a href=\"http:\/\/www.cost.eu\/COST_Actions\/ca\/CA16216\">CA16216 &#8211; OMEGA-NET<\/a>)<\/td>\n<\/tr>\n<tr>\n<td width=\"446\">\u00b7\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0CA16217 \u2013 European network of multidisciplinary research to improve the urinary stents<\/p>\n<p>(<a href=\"http:\/\/www.cost.eu\/COST_Actions\/ca\/CA16217\">CA16217 &#8211; ENIUS<\/a>)<\/td>\n<\/tr>\n<tr>\n<td width=\"446\">\u00b7\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0CA16223 \u2013 Leukemia Gene Discovery by data sharing, mining and collaboration<\/p>\n<p>(<a href=\"http:\/\/www.cost.eu\/COST_Actions\/ca\/CA16223\">CA16223 &#8211; LEGEND<\/a>)<\/td>\n<\/tr>\n<tr>\n<td width=\"446\">\u00b7\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0CA16225 \u2013 Realising the therapeutic potential of novel cardioprotective therapies<\/p>\n<p>(<a href=\"http:\/\/www.cost.eu\/COST_Actions\/ca\/CA16225\">CA16225 &#8211; EU-CARDIOPROTECTION<\/a>)<\/td>\n<\/tr>\n<tr>\n<td width=\"446\">\u00b7\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0CA16226 \u2013 Indoor living space improvement: Smart Habitat for the Elderly<\/p>\n<p>(<a href=\"http:\/\/www.cost.eu\/COST_Actions\/ca\/CA16226\">CA16226 &#8211; SHELD-ON<\/a>)<\/td>\n<\/tr>\n<tr>\n<td width=\"446\">\u00b7\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0CA16227 \u2013 Investigation and Mathematical Analysis of Avant-garde Disease Control via Mosquito Nano-Tech-Repellents (<a href=\"http:\/\/www.cost.eu\/COST_Actions\/ca\/CA16227\">CA16227 &#8211; IMAAC<\/a>)<\/td>\n<\/tr>\n<tr>\n<td width=\"446\">\u00b7\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0CA16231 \u2013 European Network of Vaccine Adjuvants (<a href=\"http:\/\/www.cost.eu\/COST_Actions\/ca\/CA16231\">CA16231 &#8211; ENOVA<\/a>)<\/td>\n<\/tr>\n<tr>\n<td width=\"446\">\u00b7\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0CA16234 \u2013 European Cleft and Craniofacial Initiative for Equality in Care (<a href=\"http:\/\/www.cost.eu\/COST_Actions\/ca\/CA16234\">CA16234 &#8211; ECCE<\/a>)<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>Sammendrag av aksjonene kan finnes under lenkene i parentes. Der finner man ogs\u00e5 lenke til en n\u00e6rmere beskrivelse av hver enkelt aksjon (<em>Memorandum of Understanding<\/em>).<\/p>\n<p><a href=\"http:\/\/k2info.w.uib.no\/files\/2017\/08\/K2nytt_2017_Uke-34_COST_New-COST-Actions-June-2017.pdf\"><strong>Her<\/strong><\/a> gis sammendragene sammen med litt tilleggsinformasjon, samt en fullstendig liste over de nye COST-aksjonene.<\/p>\n<p>Norges forsknings\u00adr\u00e5d koordinerer prosessen med henblikk p\u00e5 norsk deltakelse i COST-aksjoner. <a href=\"mailto:mailto:hh@forskningsradet.no\">Hans\u00a0Hellebostad<\/a> er kontaktperson for aksjonene innenfor medisin\/helse og kjemi.[:en]COST is a European network organization where most countries in Europe (including Norway and all EU countries) are members. An important task for COST is to promote European research cooperation by launching scientific networks (&laquo;COST actions&raquo;).<\/p>\n<p>General information about COST can be found <strong><a href=\"http:\/\/www.forskningsradet.no\/COST\">here<\/a><\/strong> and <strong><a href=\"http:\/\/www.cost.eu\/\">here<\/a><\/strong>.<\/p>\n<p>In June 2017, it was decided to initiate 35 new COST actions. A list of those relevant to medical and health research is found below.<\/p>\n<p>If you are interested in participating, please contact <strong><a href=\"mailto:mailto:mailto:hh@forskningsradet.no\">Hans Hellebostad<\/a><\/strong> in the <em>Research Council of Norway<\/em> by 15 September 2017. (This is not necessarily the last opportunity to participate in the actions, but is set as a first deadline for the Research Council&#8217;s follow-up to COST.) You can also get more detailed information about participation in COST. Application form used to participate as a participant can be found <a href=\"http:\/\/k2info.w.uib.no\/files\/2017\/08\/K2nytt_2017_Uke-34_COST_S\u00f8knad-om-deltagelse-i-COST-aksjon.doc\"><strong>here<\/strong><\/a>.<\/p>\n<p><!--more--><\/p>\n<p>In June 2017, it was decided to initiate 35 new COST actions, the following within \/ relevant to medical and health research:<\/p>\n<table>\n<tbody>\n<tr>\n<td width=\"446\">\u00b7\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0CA16203 \u2013 Stem cells of marine\/aquatic invertebrates: from basic research to innovative applications (<a href=\"http:\/\/www.cost.eu\/COST_Actions\/ca\/CA16203\">CA16203 &#8211; MARISTEM<\/a>)<\/td>\n<\/tr>\n<tr>\n<td width=\"446\">\u00b7\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0CA16205 \u2013 European Network on Understanding Gastrointestinal Absorption-related Processes (<a href=\"http:\/\/www.cost.eu\/COST_Actions\/ca\/CA16205\">CA16205 &#8211; UNGAP<\/a>)<\/td>\n<\/tr>\n<tr>\n<td width=\"446\">\u00b7\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0CA16207 \u2013 European Network for Problematic Usage of the Internet (<a href=\"http:\/\/www.cost.eu\/COST_Actions\/ca\/CA16207\">CA16207 &#8211; EU-PUI<\/a>)<\/td>\n<\/tr>\n<tr>\n<td width=\"446\">\u00b7\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0CA16210 \u2013 Maximising Impact of research in NeuroDevelopmental DisorderS<\/p>\n<p>(<a href=\"http:\/\/www.cost.eu\/COST_Actions\/ca\/CA16210\">CA16210 &#8211; MINDDS<\/a>)<\/td>\n<\/tr>\n<tr>\n<td width=\"446\">\u00b7\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0CA16216 \u2013 Coordination and Harmonization of European Occupational Cohorts<\/p>\n<p>(<a href=\"http:\/\/www.cost.eu\/COST_Actions\/ca\/CA16216\">CA16216 &#8211; OMEGA-NET<\/a>)<\/td>\n<\/tr>\n<tr>\n<td width=\"446\">\u00b7\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0CA16217 \u2013 European network of multidisciplinary research to improve the urinary stents<\/p>\n<p>(<a href=\"http:\/\/www.cost.eu\/COST_Actions\/ca\/CA16217\">CA16217 &#8211; ENIUS<\/a>)<\/td>\n<\/tr>\n<tr>\n<td width=\"446\">\u00b7\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0CA16223 \u2013 Leukemia Gene Discovery by data sharing, mining and collaboration<\/p>\n<p>(<a href=\"http:\/\/www.cost.eu\/COST_Actions\/ca\/CA16223\">CA16223 &#8211; LEGEND<\/a>)<\/td>\n<\/tr>\n<tr>\n<td width=\"446\">\u00b7\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0CA16225 \u2013 Realising the therapeutic potential of novel cardioprotective therapies<\/p>\n<p>(<a href=\"http:\/\/www.cost.eu\/COST_Actions\/ca\/CA16225\">CA16225 &#8211; EU-CARDIOPROTECTION<\/a>)<\/td>\n<\/tr>\n<tr>\n<td width=\"446\">\u00b7\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0CA16226 \u2013 Indoor living space improvement: Smart Habitat for the Elderly<\/p>\n<p>(<a href=\"http:\/\/www.cost.eu\/COST_Actions\/ca\/CA16226\">CA16226 &#8211; SHELD-ON<\/a>)<\/td>\n<\/tr>\n<tr>\n<td width=\"446\">\u00b7\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0CA16227 \u2013 Investigation and Mathematical Analysis of Avant-garde Disease Control via Mosquito Nano-Tech-Repellents (<a href=\"http:\/\/www.cost.eu\/COST_Actions\/ca\/CA16227\">CA16227 &#8211; IMAAC<\/a>)<\/td>\n<\/tr>\n<tr>\n<td width=\"446\">\u00b7\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0CA16231 \u2013 European Network of Vaccine Adjuvants (<a href=\"http:\/\/www.cost.eu\/COST_Actions\/ca\/CA16231\">CA16231 &#8211; ENOVA<\/a>)<\/td>\n<\/tr>\n<tr>\n<td width=\"446\">\u00b7\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0CA16234 \u2013 European Cleft and Craniofacial Initiative for Equality in Care (<a href=\"http:\/\/www.cost.eu\/COST_Actions\/ca\/CA16234\">CA16234 &#8211; ECCE<\/a>)<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>A summary of the actions can be found under the links in brackets. There is also a link for a more detailed description of each operation (<em>Memorandum of Understanding<\/em>).<\/p>\n<p><a href=\"http:\/\/k2info.w.uib.no\/files\/2017\/08\/K2nytt_2017_Uke-34_COST_New-COST-Actions-June-2017.pdf\"><strong>Here<\/strong><\/a> are the summaries together with some additional information, as well as a complete list of the new COST actions.<\/p>\n<p>The <em>Research Council of Norway<\/em> coordinates the process for Norwegian participation in COST actions. <a href=\"mailto:mailto:mailto:mailto:hh@forskningsradet.no\">Hans Hellebostad<\/a> is the contact person for activities in medicine \/ health and chemistry.[:]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>[:no]COST er en europeisk nettverksorganisasjon der de fleste landene i Europa (herunder Norge og alle EU-landene) er medlemmer. En viktig oppgave for COST er \u00e5 fremme europeisk forskningssamarbeid ved \u00e5 igangsette vitenskapelige nettverk (&laquo;COST-aksjoner&raquo;). Generell informasjon om COST finnes her&hellip;<\/p>\n<p class=\"more-link-p\"><a class=\"more-link\" href=\"https:\/\/k2info.w.uib.no\/nb_no\/2017\/08\/25\/cost-nye-nettverk-innen-medisinsk-og-helsefaglig-forskning\/\">Read more &rarr;<\/a><\/p>\n","protected":false},"author":3699,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[44],"tags":[],"class_list":["post-12679","post","type-post","status-publish","format-standard","hentry","category-nyheter"],"_links":{"self":[{"href":"https:\/\/k2info.w.uib.no\/nb_no\/wp-json\/wp\/v2\/posts\/12679","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/k2info.w.uib.no\/nb_no\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/k2info.w.uib.no\/nb_no\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/k2info.w.uib.no\/nb_no\/wp-json\/wp\/v2\/users\/3699"}],"replies":[{"embeddable":true,"href":"https:\/\/k2info.w.uib.no\/nb_no\/wp-json\/wp\/v2\/comments?post=12679"}],"version-history":[{"count":3,"href":"https:\/\/k2info.w.uib.no\/nb_no\/wp-json\/wp\/v2\/posts\/12679\/revisions"}],"predecessor-version":[{"id":12684,"href":"https:\/\/k2info.w.uib.no\/nb_no\/wp-json\/wp\/v2\/posts\/12679\/revisions\/12684"}],"wp:attachment":[{"href":"https:\/\/k2info.w.uib.no\/nb_no\/wp-json\/wp\/v2\/media?parent=12679"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/k2info.w.uib.no\/nb_no\/wp-json\/wp\/v2\/categories?post=12679"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/k2info.w.uib.no\/nb_no\/wp-json\/wp\/v2\/tags?post=12679"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}